Charles River Laboratories International

Charles River Laboratories International (CRL)

$196.05

+1.93

(+0.99%)

Market is closed - opens 7 PM, 31 May 2023

Performance

  • $194.24
    $199.24
    $196.05
    downward going graph

    0.92%

    Downside

    Day's Volatility :2.51%

    Upside

    1.6%

    downward going graph
  • $181.22
    $262.00
    $196.05
    downward going graph

    7.56%

    Downside

    52 Weeks Volatility :30.83%

    Upside

    25.17%

    downward going graph

Returns

PeriodCharles River Laboratories International
3 Months
-10.62%
6 Months
-14.23%
1 Year
-16.25%
3 Years
9.03%

Highlights

Market Capitalization
9.9B
Book Value
$60.74
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
9.65
PE Ratio
20.12
PEG Ratio
1.2
Wall Street Target Price
249.0
Profit Margin
12.13%
Operating Margin TTM
16.41%
Return On Assets TTM
5.68%
Return On Equity TTM
17.21%
Revenue TTM
4.1B
Revenue Per Share TTM
80.34
Quarterly Revenue Growth YOY
12.6%
Gross Profit TTM
1.5B
EBITDA
977.2M
Diluted Eps TTM
9.65
Quarterly Earnings Growth YOY
0.11
EPS Estimate Current Year
10.36
EPS Estimate Next Year
12.09
EPS Estimate Current Quarter
2.59
EPS Estimate Next Quarter
2.48

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Charles River Laboratories International(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
16
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 27.01%

Current $196.05
Target $249.00

Company Financials

FY17Y/Y Change
Revenue
1.9B
↑ 10.48%
Net Income
123.4M
↓ 20.3%
Net Profit Margin
6.64%
↓ 2.56%
FY18Y/Y Change
Revenue
2.3B
↑ 21.99%
Net Income
226.4M
↑ 83.51%
Net Profit Margin
9.99%
↑ 3.35%
FY19Y/Y Change
Revenue
2.6B
↑ 15.67%
Net Income
252.0M
↑ 11.33%
Net Profit Margin
9.61%
↓ 0.38%
FY20Y/Y Change
Revenue
2.9B
↑ 11.55%
Net Income
364.3M
↑ 44.55%
Net Profit Margin
12.46%
↑ 2.85%
FY21Y/Y Change
Revenue
3.5B
↑ 21.08%
Net Income
391.0M
↑ 7.32%
Net Profit Margin
11.04%
↓ 1.42%
FY22Y/Y Change
Revenue
4.0B
↑ 12.31%
Net Income
486.2M
↑ 24.36%
Net Profit Margin
12.23%
↑ 1.19%
Q4 FY21Q/Q Change
Revenue
905.1M
↑ 1.02%
Net Income
137.6M
↑ 33.02%
Net Profit Margin
15.2%
↑ 3.66%
Q1 FY22Q/Q Change
Revenue
913.9M
↑ 0.98%
Net Income
93.0M
↓ 32.39%
Net Profit Margin
10.18%
↓ 5.02%
Q2 FY22Q/Q Change
Revenue
973.1M
↑ 6.48%
Net Income
109.3M
↑ 17.52%
Net Profit Margin
11.23%
↑ 1.05%
Q3 FY22Q/Q Change
Revenue
989.2M
↑ 1.65%
Net Income
96.5M
↓ 11.75%
Net Profit Margin
9.75%
↓ 1.48%
Q4 FY22Q/Q Change
Revenue
1.1B
↑ 11.19%
Net Income
187.4M
↑ 94.26%
Net Profit Margin
17.04%
↑ 7.29%
Q1 FY23Q/Q Change
Revenue
1.0B
↓ 6.41%
Net Income
104.0M
↓ 44.53%
Net Profit Margin
10.1%
↓ 6.94%
FY17Y/Y Change
Total Assets
2.9B
↑ 8.04%
Total Liabilities
1.9B
↑ 0.65%
FY18Y/Y Change
Total Assets
3.9B
↑ 31.6%
Total Liabilities
2.5B
↑ 33.57%
FY19Y/Y Change
Total Assets
4.7B
↑ 21.7%
Total Liabilities
3.0B
↑ 20.21%
FY20Y/Y Change
Total Assets
5.5B
↑ 17.01%
Total Liabilities
3.3B
↑ 10.6%
FY21Y/Y Change
Total Assets
7.0B
↑ 27.93%
Total Liabilities
4.4B
↑ 32.42%
FY22Y/Y Change
Total Assets
7.6B
↑ 8.24%
Total Liabilities
4.6B
↑ 3.32%
Q4 FY21Q/Q Change
Total Assets
7.0B
↓ 0.48%
Total Liabilities
4.4B
↓ 3.52%
Q1 FY22Q/Q Change
Total Assets
7.1B
↑ 0.72%
Total Liabilities
4.4B
↓ 0.63%
Q2 FY22Q/Q Change
Total Assets
7.5B
↑ 6.42%
Total Liabilities
4.8B
↑ 9.81%
Q3 FY22Q/Q Change
Total Assets
7.4B
↓ 1.95%
Total Liabilities
4.7B
↓ 2.59%
Q4 FY22Q/Q Change
Total Assets
7.6B
↑ 2.98%
Total Liabilities
4.6B
↓ 2.79%
Q1 FY23Q/Q Change
Total Assets
7.7B
↑ 1.27%
Total Liabilities
4.5B
↓ 0.8%
FY17Y/Y Change
Operating Cash Flow
316.3M
↑ 6.02%
Investing Cash Flow
-72.6M
↓ 89.42%
Financing Cash Flow
-208.5M
↓ 153.36%
FY18Y/Y Change
Operating Cash Flow
441.1M
↑ 39.48%
Investing Cash Flow
-955.0M
↑ 1215.68%
Financing Cash Flow
558.1M
↓ 367.69%
FY19Y/Y Change
Operating Cash Flow
480.9M
↑ 9.02%
Investing Cash Flow
-681.5M
↓ 28.64%
Financing Cash Flow
231.9M
↓ 58.44%
FY20Y/Y Change
Operating Cash Flow
546.6M
↑ 13.65%
Investing Cash Flow
-601.5M
↓ 11.73%
Financing Cash Flow
47.2M
↓ 79.63%
FY21Y/Y Change
Operating Cash Flow
760.8M
↑ 39.19%
Investing Cash Flow
-1.4B
↑ 139.04%
Financing Cash Flow
672.6M
↑ 1323.55%
FY22Y/Y Change
Operating Cash Flow
619.6M
↓ 18.55%
Investing Cash Flow
-607.9M
↓ 57.72%
Financing Cash Flow
-42.4M
↓ 106.3%
Q4 FY21Q/Q Change
Operating Cash Flow
229.3M
↑ 31.21%
Investing Cash Flow
9.3M
↓ 102.62%
Financing Cash Flow
-219.0M
↓ 222.4%
Q1 FY22Q/Q Change
Operating Cash Flow
102.6M
↓ 55.23%
Investing Cash Flow
-98.0M
↓ 1153.02%
Financing Cash Flow
-13.3M
↓ 93.93%
Q2 FY22Q/Q Change
Operating Cash Flow
149.5M
↑ 45.64%
Investing Cash Flow
-462.1M
↑ 371.52%
Financing Cash Flow
271.4M
↓ 2143.48%
Q3 FY22Q/Q Change
Operating Cash Flow
132.8M
↓ 11.17%
Investing Cash Flow
-652.3M
↑ 41.16%
Financing Cash Flow
-51.6M
↓ 119.01%
Q4 FY22Q/Q Change
Operating Cash Flow
234.8M
↑ 76.8%
Investing Cash Flow
44.4M
↓ 106.8%
Financing Cash Flow
-249.0M
↑ 382.53%
Q1 FY23Q/Q Change
Operating Cash Flow
109.4M
↓ 53.41%
Investing Cash Flow
-168.6M
↓ 479.92%
Financing Cash Flow
25.2M
↓ 110.14%

Technicals Summary

Sell

Neutral

Buy

Charles River Laboratories International is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Institutional Holdings

  • Vanguard Group Inc

    11.75%
  • BlackRock Inc

    9.69%
  • T. Rowe Price Associates, Inc.

    4.90%
  • State Street Corporation

    4.01%
  • Kayne Anderson Rudnick Investment Management LLC

    3.16%
  • ClearBridge Advisors, LLC

    2.75%

Company Information

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

Organization
Charles River Laboratories International
Employees
20000
CEO
Mr. James C. Foster J.D.
Industry
Commercial Services

FAQs